Entrada Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TRDA research report →
Range $11 – $17
Price Chart
About the company
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches.
- CEO
- Dipal Doshi
- IPO
- 2021
- Employees
- 152
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on TRDA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $170.30M
- P/E
- -1.21
- PEG
- 0.03
- P/S
- 45.68
- P/B
- 0.99
- EV/EBITDA
- -0.72
- Div Yield
- 0.00%
- Gross Margin
- 57.48%
- Op Margin
- -4303.82%
- Net Margin
- -4057.98%
- ROE
- -64.00%
- ROIC
- -69.68%
Latest fiscal year · YoY change
- Revenue
- $25.42M-87.9%
- Gross Profit
- $21.32M-89.9%
- Op Income
- $-155,998,000
- Net Income
- $-143,750,000-319.0%
- EPS
- $-3.47-297.2%
- OCF Growth
- -209.2%
- FCF Growth
- -189.7%
- 52W High
- $16.45
- 52W Low
- $4.11
- 50D MA
- $5.43
- 200D MA
- $8.33
- Beta
- -0.24
- RSI (14)
- 41
- Avg Volume
- 397.92K
No earnings-call transcripts are available for TRDA yet.
- Free Float
- 59.1%
- Shares Outstanding
- 39.15M
- Float Shares
- 23.12M
of shares held by institutions
130 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Baker Bros. Advisors LP | 5.07M | 0 |
| 5am Venture Management, LLC | 3.78M | ▼ 271.73K |
| Blackrock, Inc. | 3.24M | ▲ 653.77K |
| Merck & Co., Inc. | 1.74M | 0 |
| Vanguard Group Inc | 1.63M | ▲ 28.23K |
| Trails Edge Capital Partners, LP | 1.43M | ▲ 1.43M |
| Vanguard Capital Management LLC | 1.27M | 0 |
| Tcg Crossover Management, LLC | 1.06M | 0 |
| Wellington Management Group Llp | 954.42K | 0 |
| Stepstone Group LP | 761.28K | 0 |
| Geode Capital Management, LLC | 708.49K | ▼ 8.94K |
| Acadian Asset Management LLC | 648.97K | ▲ 248.11K |
Held by 144 ETFs
Biggest fund positions in TRDA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 4, 26 | MPM BIOVENTURES 2018, L.P. | sell | 38,500 |
| Sep 8, 26 | MPM BIOVENTURES 2018, L.P. | sell | 192,500 |
| Sep 9, 26 | MPM BIOVENTURES 2018, L.P. | sell | 28,837 |
| Sep 4, 26 | MPM BioVentures 2014, L.P. | sell | 38,500 |
| Sep 8, 26 | MPM BioVentures 2014, L.P. | sell | 192,500 |
| Sep 9, 26 | MPM BioVentures 2014, L.P. | sell | 28,837 |
| Sep 1, 26 | MPM BIOVENTURES 2018, L.P. | sell | 29,088 |
| Sep 2, 26 | MPM BIOVENTURES 2018, L.P. | sell | 25,131 |
| Sep 3, 26 | MPM BIOVENTURES 2018, L.P. | sell | 32,263 |
| Sep 1, 26 | MPM BioVentures 2014, L.P. | sell | 29,088 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TRDA coverage
Recent articles, reports, and earnings notes.
No research on TRDA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TRDA report →Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Increased Dose of 15 mg/kg in Entrada Therapeutics' ELEVATE-45-201 Study
globenewswire.com · Nov 18
Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Misses Revenue Estimates
zacks.com · Nov 5
Entrada Therapeutics Reports Third Quarter 2026 Financial Results
globenewswire.com · Nov 5
Head to Head Review: Entrada Therapeutics (NASDAQ:TRDA) versus X4 Pharmaceuticals (NASDAQ:XFOR)
defenseworld.net · Oct 22
Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer
globenewswire.com · Oct 21
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study
globenewswire.com · Oct 14
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45
globenewswire.com · Oct 14
Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity
seekingalpha.com · Oct 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.